[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643888":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":39,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":78,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Gazi University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Morbid obese patients initiating GLP-1 receptor agonist therapy",null,[12],"Drug: GLP-1 receptor agonist therapy",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","GLP-1 receptor agonist therapy","Participants will receive GLP-1 receptor agonist treatment as part of routine clinical care. The study does not assign treatment but prospectively evaluates proctologic outcomes following treatment initiation.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Mesut Yavaş, MD, Assistant of Professor","CONTACT","+903122025719","mesutyavas@gazi.edu.tr",[26],{"facility":27,"status":10,"city":28,"state":10,"zip":10,"country":29,"countryCode":10,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Gazi University Faculty of Medicine","Ankara","Turkey (Türkiye)",{"type":31,"coordinates":32},"Point",[33,34],32.85427,39.91987,{"lat":34,"lon":33},[37],{"name":38,"role":22,"phone":23,"phoneExt":10,"email":24},"mESUT Yavaş, MD",{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Mesut YAVAS","Principal Investigator","100643888","glp-1-receptor-agonists-and-early-proctologic-effects-in-morbid-obesity-100643888",false,"NCT07668765","GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity","Early Proctologic Effects of GLP-1 Receptor Agonist Therapy in Morbidly Obese Patients: A Prospective Cohort Study With Baseline and 3-Month Proctologic Assessment","GLP-PROCT","Inclusion Criteria:\n\n* Age ≥18 years\n* Morbid obesity (BMI ≥40 kg\u002Fm² or BMI ≥35 kg\u002Fm² with obesity-related comorbidities)\n* Newly prescribed GLP-1 receptor agonist therapy\n* Ability and willingness to provide written informed consent\n* Ability to attend 3-month follow-up visit\n\nExclusion Criteria:\n\n* Inflammatory bowel disease\n* Perianal Crohn's disease\n* History of anorectal malignancy\n* Previous pelvic radiotherapy\n* Anorectal surgery within the previous 3 months\n* Pregnancy\n* Neurogenic bowel dysfunction\n* Inability to comply with follow-up visits\n* Discontinuation of GLP-1 receptor agonist therapy before follow-up assessment\n* Active anorectal infection or abscess","ALL","18 Years",{"count":54,"type":55},100,"ESTIMATED","3 Months","OBSERVATIONAL","Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.",[60,61,62,63,64],"Morbid Obesity","Anorectal Diseases","Drug-Related Side Effects and Adverse Reactions","Constipation","Diarrhea",[66,67,68,69,70,71,72,73,74,75,76,77],"GLP-1 receptor agonist","obesity","anorectal symptoms","hemorrhoids","anal fissure","constipation","semaglutide","tirzepatide","proctologic examination","bowel habits","anorectal disease","proctology","NOT_YET_RECRUITING","2026-06-23",{"date":81,"type":82},"2026-06-25","ACTUAL",{"date":84,"type":55},"2026-08",{"date":86,"type":55},"2027-05",{"name":5,"class":6},1]